PubGene and BGI* are collaborating to develop the Coremine Oncology. BGI is providing cancer genomic data and exploring test-cases using the tools under development by PubGene. Patient data from BGI includes tumor profiles from DNA sequencing, copy number changes and RNA expression. Areas of interest include the ability to rank findings by importance, link implicated drug targets to drugs (both approved drugs and candidates in clinical trials), rank drugs by target affinity and to visualize findings in the context of signalling pathways.
*BGI is the Beijing Genomics Institute.